We were unable to send the article.
Five members have been selected as the new and permanent BioVentures Board of Directors.
Board members will serve three-year terms and replace an interim board created after BioVentures became a private, nonprofit limited liability company in late 2016.
BioVentures is a technology commercialization organization and startup incubator affiliated with the University of Arkansas for Medical Sciences.
The five board members are:
Louise Epstein, director of university partnerships for the Walton Personal Philanthropy Group.
Remi Barbier, founding president and CEO of Cassava Sciences.
Kevin Heyeck, a venture partner in 6 Dimensions Capital, a leading U.S. and China–focused investment group specializing in health care and life sciences. He is also a director of Hibercell and Ultivue.
Bobby W. Sandage Jr., a general partner in the Cultivation Capital Life Sciences venture fund. He is also president and CEO of Euclises Pharmaceuticals Inc.
Steve Abell, vice president of strategic innovations and investments for Arkansas Blue Cross and Blue Shield. Also, he is executive vice president of USAble Corporation, Blue Cross’s wholly owned subsidiary.